Originally developed as a phosphodiesterase inhibitor, the small molecule inhibitor ibudilast was found to allosterically inhibit MIF and showed efficacy in a phase II clinical trial of multiple sclerosis patients (170, 171). Here, MIF is linked to multiple sclerosis.